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Slllmnlary 
When mast cells are activated through  their immunoglobulin  (Ig)E receptors,  release of low 
molecular weight mediators like histamine is followed by secretion of multiple cytokines, including 
interleukin (IL)-3, IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor.  Here we 
report that  stimulated  mast cells  also synthesize IL-13 mRNA and protein;  secretion of this 
cytokine may be of particular importance because of its ability to stimulate IgE expression. IL-13 
transcripts  detected by a semiquantitative reverse transcriptase--mediated  polymerase chain reaction 
assay were induced within 30 min after stimulation of mast cells by dinitrophenyl plus monoclonal 
IgE anti-dinitrophenyl,  and peaked at about 1 h. Within 3 h of IgE stimulation,  secreted IL-13 
bioactivity, estimated by proliferation of an IL-13-dependent cell line,  reached levels equivalent 
to 1-2 ng/ml of IL-13. When added to human B lymphocytes, the mast cell-derived IL-13 activity 
(like bone fide IL-13) induced Ig CE transcripts, DNA recombination characteristic of the isotype 
switch to Ce, and the secretion of IgE protein.  These results suggest a model of local positive 
feedback interactions between mast cells and B cells, which could play a role in the pathogenesis 
of atopy. 
M 
ast cells are now recognized as an important source of 
. cytokines possessing proinflammatory, differentiative, 
and growth-promoting capabilities (reviewed in references 1 
and 2) and have been postulated to participate in immuno- 
regulatory cytokine cascades,  both as initiators  (3), as well 
as amplifiers  (1) of cytokine responses.  Moreover,  through 
direct cell contacts mediated by specific cell surface structures, 
mast cells and their secreted products are speculated to par- 
ticipate in a form of the immunological synapse, complexing 
with or modifying the functions of other cells under a va- 
riety of circumstances  (1). 
The spectrum of cytokines elaborated by mast cells in re- 
sponse to immunological  and pharmacological  stimulation 
is quite broad and includes IL-3, IL-4, IL-5, and GM-CSE 
The genes for these cytokines are all colocalized on mouse 
chromosome 11 (4--6) and possess genomic structural features 
suggesting that they may have arisen through gene duplica- 
tion. Recently, an IL-4-1ike cytokine termed IL-13 has been 
identified (7), and its gene has been shown to lie on chromo- 
some 11, near the IL-4 gene (8). This same region is associated 
with certain forms of atopic allergic disease in humans (9). 
IL-13 shares  many biologic properties with IL-4, including 
suppressive  effects  upon  macrophage  activation  (10,  11), 
proliferative and differentiative effects upon hematopoietic pro- 
genitor cells (12), and promoting B cell growth and immu- 
noglobulin class switching to IgE (references 7 and 13, reviewed 
in reference 14). Unlike IL-4, however, IL-13 cannot stimu- 
late T  cells.  Thus,  IL-13 may mediate functions associated 
with IL-4 under conditions in which IL-4-mediated T  cell 
effects  would be disadvantageous. 
In this report, we show that human mast cell and basophilic 
cell lines,  primary cultures of murine bone marrow-derived 
cultured mast cells (BMMC), t and the cloned murine mast 
cell line C1.MC/C57.1  transcribe IL-13 in response to im- 
munological stimulation.  We also demonstrate that murine 
mast ceils secrete significant  amounts of IL-13 under these 
conditions. The potential importance of these findings in im- 
munological  function  of mast  cells  is discussed. 
Materials  and Methods 
Mast  Cells and  Cell Activations.  The  human  mast  cell line, 
HMC-1  (15), was obtained  from  Dr. Joseph  Butterfield  (Mayo 
Clinic, Rochester, MN) and maintained in Iscove's Modified Es- 
sential Medium,  supplemented with 10% FCS, 1.2 mM ot-thio- 
glycerol (Sigma Chemical Co., St. Louis, MO), 100 U/ml peni- 
cillin, and 0.1 rag/m1 streptomycin. The human basophilic cell line, 
KU812 (16), was obtained from Dr. John Rivera, National Insti- 
1  Abbreviations used in this  paper: BMMC, bone marrow-derived cultured 
mast cells; CSA, cyclosporin  A; gCe, germline CA; G3PDH, glyceraldehyde- 
3-phosphate dehydrogenase; HMC, human mast cell line; mRNA, 
messenger RNA; pCe, productive, rearranged IgE; rhIL-13, recombinant 
human IL-13; RTPCR, reverse transcriptase-mediated polymerase  chain 
reaction. 
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rine mast cell  line,  C1.MC/C57.1  (17),  was obtained from Dr. 
Stephen Galli (Beth Israel Hospital, Boston, MA).  Primary cul- 
tures  of IL-3-dependent  BMMC  were  prepared  from  6-12-wk 
BALB/c mice, as follows: Mice were killed by cervical dislocation, 
and bone marrow was aseptically flushed  from femurs and tibias 
into  RPMI  1640  medium containing  4  mM t-glutamine,  5  x 
10 -s M  2-mercaptoethanol,  1 mM sodium pyruvate,  100 U/ml 
penicillin,  0.1  mg/ml streptomycin, 0.1  mM nonessential amino 
acids,  10%  heat-inactivated FCS,  and  10% medium conditioned 
by WEHI-3 cells (TIB 68;  American Type Culture  Collection, 
tLockviUe, MD) as a source of Ib3. The bone marrow cells were 
then collected by centrifugation at 400 g  for 10 min and main- 
tained  at a density of 3-4  x  105 cells/ml in  the same medium 
with biweekly replacement of used  medium with  fresh.  Flasks 
(75 cm  ~) were kept at 37~  in a 5% CO2, humidified  atmosphere. 
BMMC obtained after 3-4 wk culture were >95% mast cells, as 
demonstrated by morphologic analysis. For high affinity IgE receptor 
(FqRI)-dependent  activation,  mast cells  were sensitized with  a 
monoclonal murine IgE anti-DNP antibody (18) obtained from 
Dr. David Katz (Biomedical Research Institute, La Jolla, CA) (19) 
and challenged with 40 ng/ml DNP30-40 human serum albumin 
(Sigma Chemical Co.) at a cell density of 2  x  106 cells/ml. 
Isolation of RNA  and Reverse Transcriptase-mediated Polymerase 
Chain Reaction (RTPCR).  Cellular RNA was isolated from mast 
cells by the guanidine  thiocyanate/CsC1 centrifugation  method, 
as described (18).  Levels of cytokine messenger RNA  (mRNA) 
were assessed by a semiquantitative reverse transcriptase-mediated 
polymerase chain reaction. As a strategy for obtaining semiquan- 
titative results from our RTPCR reactions,  products were detected 
by quantitating  incorporated  radioactivity,  and  the  number  of 
amplification cycles chosen empirically for each primer pair was 
such that the maximum signal intensity for a set of samples was 
within the linear portion of a product vs. template amplification 
curve (20). After reverse transcription of each RNA sample using 
random primers, each sample was subjected to an initial assay for 
amplifiable  cDNA,  using  primers  specific  for glyceraldehyde-3- 
phosphate dehydrogenase (G3PDH) mRNA, which is not known 
to vary under  our cellular incubation  conditions.  Based  on the 
amount of G3PDH PCR product in this assay, aliquots of reverse 
transcriptase product representing equivalent amounts of G3PDH 
cDNA were amplified using primers for Ib13, Ib4, and again for 
G3PDH, as follows:  RNA (4 #g) was reverse transcribed, using 
an Rnase H- reverse transcriptase (Superscript;  Life Technologies, 
Inc., Gaithersburg, MD) according to the manufacturer's condi- 
tions.  The resultant cDNA was immediately diluted with H20 
to a final volume of 200/zl,  without  heating or Rnase H  treat- 
ment. Polymerase chain reaction was performed in thin wall re- 
action tubes  (Perkin Elmer Cetus,  Norwalk,  CT)  in a reaction 
mixture (50/zl) containing cDNA,  200/~M each dNTP,  1 /zCi 
ot-[32p]dCTP  (3,000  Ci/mmol,  Dupont-NEN,  Boston,  MA), 
1/~M each primer, 5% DMSO (Sigma Chemical Co.), and 2.5  U 
AmpliTaq DNA polymerase (Perkin Elmer Cetus) in reaction buffer 
supplied by the manufacturer. Primers are listed in Table 1. Am- 
plifications  were performed in  a  thermocycler (GeneAmp PCR 
System 9,600;  Perkin Elmer Cetus) as follows: 94~  3 min; fol- 
lowed by 21-32 amplification cycles (94~  45 s; primer annealing 
temperature as specified in Table 1, I min; 72~  I min); and main- 
Table  1.  PCR Primers, Product Sizes, and Annealing Temperatures 
RNA/DNA  Genbank 
detected*  accession  no.  Primer pair (upper strand;  lower strand)  Size  Temperature 
m-IL-4  X05253 
m-IL-13  L13028 
m-TNF-a  Y00467 
m-G3PDH  M32599 
h-IL-13  L06081 
h-G3PDH  X01677 
h-gCe  X56795 
h-pC~  M99403  (VH5) 
J00222  (Ce-1) 
h-pCe  X56795  (S/~) 
(DNA)  J00222  (Se) 
~ 
ATGGGTCTCAACCCCCAGCTAGT;  399  62.5 
GCTCTTTAGGCTTTCCAGGAAGTC 
ATGGCGCTCTGGGTGACTGCAGTCC;  392  67 
GAAGGGGCCGTGGCGAAACAGTTGC 
CACAGAAAGCAGGATCCGCG;  383  59 
GGCACCACTAGTTGGTTGTC 
GCCACCCAGAAGACTGTGGATGGC;  446  64 
CATGTAGGCCATGAGGTCCACCAC 
CCACGGTCATTGCTCTCACTTGCC;  263  66 
CCTTGTGCGGGCAGAATCCGCTCA 
GCTCAGACACCATGGGGAAGGT;  470  64 
GTGGTGCAGGAGGCATTGCTGA 
AGGCTCCACTGCCCGGCACAGAAAT;  484  67 
ACTGTAAGATCTTCTACGGTGGGCGGGGTGAA 
TCTGAGGTGCAGCTGGTGGAGTCTG;  657  60 
GACGCTGAAGGTTTTGTTGTCG 
GGCCTCTAGACAAGGGGACCTGCTCATTTTTATC;  0.7-4  58 
GGCCGAATTCTAGTGCGGTCTGTACAGCGTGGC  kb 
* Primers designed for detection of RNA unless noted,  m, murine; h, human. 
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were analyzed  by electrophoresis on 7% acrylamide  (Long Ranger; 
AT Biochem, Malvem, PA) Tris-borate EDTA gels, followed by 
autoradiography  and quantitation by Phosphorimage analysis  (Mo- 
lecular Dynamics, Sunnyvale, CA). DNA sizes were determined 
using mobility standards derived by T4 DNA polymerase end- 
labeling of Gel Marker DNA (Research Genetics, Huntsville, AL). 
Measurement of  lL,13 Proliferative  Bioactivity.  To assay  IL-13  bio- 
activity in crude superuatants, we had to take into account the fact 
that most of the activities of this cytokine are shared with Ib4, 
which is known to be secreted  by mast cells. To avoid  confounding 
II.-4 effects, we assayed  11,-13 activity in supernatants from murine 
mast cells using human cells as responders, since murine Ib13 cross- 
reacts with human IL-13 receptors, whereas murine Ib4 is species- 
specific. The Ib13-responsive human premyeloid  cell line TF-1 (21) 
was obtained from G. Zurawski (DNAX Research Institute, Palo 
Alto, CA) and maintained  in RPMI-1640, supplemented  with 10% 
heat inactivated  fetal  bovine serum, 100 U/rrd penicillin, 0.1 mg/ml 
streptomycin, and 2.5 ng/ml recombinant human Ib13 (rh-Ib13) 
(Peprotech Inc., Rock Hill, NJ). 
TF-1 ceils used to measure IL-13 bioactivity were starved of Ib 
13 for 48 h before exposure to mast cell supernatants. To assess 
the proliferative response of TF-1 cells to these superuatants, qua- 
druplicate 100-#1 aliquots of serially  diluted supernatants  were added 
to 96-well flat-bottom plates containing 40,000 TF-1 cells in 100 
/~1 of KPMI 1640, 10% fetal bovine serum, and antibiotics. Cells 
were cultured for 42 h and then pulsed for 6 h with 1.0 #Ci 
[3H]thymidine (6.7 Ci/mM; Dupont-NEN), harvested  onto glass 
fiber falter strips with a multiple sample harvester (Skatron, Lier, 
Sterling, VA) and processed for scintillation counting. The max- 
imal proliferative  response of  TF-1 ceils to IL-13  was three-fold over 
Ib13-starved cells and was achieved with 1 ng/ml rhlb13. 
Stimulation of  lgE Expression in Human B Lymphocytes.  Human 
B lymphocytes  were purified by positive selection from PBMC ob- 
tained by Ficoll  centrifugation  of  leukophoresis samples from normal 
donors. PBMC  were incubated  with anti-CD19 mAB-coated  ferrous 
beads (DYNAL Inc., Great Neck, NY), followed  by magnetic sepa- 
ration of B lymphocytes from nonreacting cells. B lymphocytes 
were cultured at a density of one million cells/rrd  in Iscove's  medium, 
containing 10% FCS, 2.5  x  10 -5 M/~-mercaptoethanol, 100 U/rrd 
penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine.  Cul- 
tures were stimulated with 2 mg/ml of anti-CD40 mAb 62;6.1 
(kindly provided by Dr. J. Banchereau, Schering-Plough Research 
Institute, Lyon, France) or anti-CD40 mAb EA-5 (obtained from 
Biosource International Inc., Camarillo, CA). B lymphocytes  were 
cultured with anti-CD40 mAb alone, or with 10 ng/ml of recom- 
binant human Ib4 (kindly provided by Dr. A. Levine, Monsanto 
Co.,  St.  Louis, MO),  or with 50%  (C1.MC/C57.1)  or  100% 
(BMMC) culture  volumes from either resting or  IgE/antigen- 
stimulated mast cells, as described above. 
After 6 d of culture, KNA was prepared from three to five  mil- 
lion cells, as described  above, and genomic DNA was prepared from 
a similar  number of  cells. Reverse transcription of cDNA and semi- 
quantitative PCR analysis for germline Ce (gCe) and productive 
Ce (pCe) was as described above with primers shown in Table 1, 
using  60~  annealing  steps in  both  cases, and  28  cycles of 
amplification for gCe, or 30 cycles of amplification for pCe. To 
detect #-e switch recombination, S#-Se switch junctions  were 
amplified from genomic DNA as described (22). When applied 
to a population of  cells undergoing independent S/x-Se recombina- 
tion events, this protocol yields a ladder of  bands. These bands vary 
in size, because the size of each composite switch region retained 
on the chromosome after switching varies over several kilobases, 
depending on the exact position of the recombination breakpoints 
within S# and Se. In brief, 500 ng B cell DNA, determined by 
fluorimetric analysis  and dissolved  in a 25-gl volume, was amplified 
for a total of 32 cycles, using a primer 5' to S# and a primer Y 
to Se, after which samples were electrophoresed,  blotted, and hy- 
bridized with a 5' Sg probe (22). Primers used are listed in Table 1. 
Measurement of lgE and 11,4 by ELISA.  To measure IgE pro- 
tein expression, triplicate cultures of 200,000 human B lympho- 
cytes were maintained for each culture condition. After 12 d, IgE 
levels in supernatants from these cultures were analyzed  by ELISA, 
as previously  described  (23). Murine 1I.-4  was assayed  using an ELISA 
kit (Endogen, Inc., Boston, MA) according to the manufacturer's 
instructions. Cytokine concentrations in nanograms per milliliter 
were obtained by regression analyses  using a curve generated from 
standard cytokine preparations. 
Results 
BMMC and a Mast Cell Line Transcribe IL-13 RNA in Re- 
sponse to  Immunologic  Stimulation,  PMA,  or  Calcium  Iono- 
phore.  Mast cells produce IL-4 after stimulation through their 
IgE receptors  or in response to calcium ionophore (24). We 
sought to determine whether IL-13, an IL-4-1ike molecule 
possessing many biologic properties in common with IL-4, 
was also produced by mast cells. As only low levels of mKNA 
specific for IL-4 are observed in mast cells after stimulation, 
we used an RTPCK assay for detection of IL-13. 
We first determined whether IL-13 mRNA was expressed 
in BMMC stimulated with IgE and specific antigen, or in 
response  to pharmacologic stimulation through protein ki- 
nase C (PMA) or calcium flux (A23187) (Fig.  1 A). IL-13- 
specific product was not detected in control unstimulated 
BMMC. Exposure of cells to IgE without cross-linking an- 
tigen resulted in low level induction of IL-13-specific product 
(twofold over the corresponding region of the unstimulated 
lane), whereas stimulation was *32-fold after cross-linking 
of the IgE by multivalent antigen, with peak expression oc- 
curring by 1 h. Treatment with either PMA (50 ng/ml), or 
calcium ionophore A23187 (1 gM), for 3 h also resulted in 
high level induction. Sequence analysis of cloned IL- 13 PCR 
product indicated complete agreement with the published 
cDNA sequence  (25)  (data not shown). 
Because IL-13 and IL-4 mediate similar immunological phe- 
nomena, we also examined the induction pattern of IL-4 in 
BMMC under these conditions. The induction kinetics of 
IL-4 RNA were similar to those of IL-13,  but with peak 
expression occurring somewhat more broadly from 1 to 3 h. 
Unlike IL-13, IL-4 RNA was not induced by PMA treat- 
ment, but was inducible by calcium ionophore, as demon- 
strated previously in mast cell lines (24). Also, the induction 
characteristics of IL-13 and IL-4 were similar for BMMC main- 
tained for as long as 7 wk in culture. Thus, IL-13 and IL-4 
appear  to be coordinately expressed  in response  to IgE or 
calcium-mediated signals,  but not to PMA/protein kinase 
C-mediated signals, suggesting that IL-13 and IL-4 may be 
separately  regulated under some circumstances. 
To strengthen the conclusion that mast cells (as opposed 
to some other minor cell population in our BMMC cultures) 
are capable of IL-13 RNA synthesis, we investigated whether 
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antigen, PMA, and calcium ionophore. (A) BMMC cultured for 4 wk 
in IL-3-containing  medium and stimulated  with IgE and specific  antigen, 
PMA, or calcium ionophore, as indicated, were analyzed by RTPCR. 
Amplification  cycles  used  were  as follows:  IL-D, 21 cycles;  IL-4,  31 cycles; 
and G3PDH, 21 cycles. (B) C1.MC/C57.1 cells stimulated with IgE and 
specific antigen, PMA, or calcium ionophore A23187, as indicated, were 
analyzed by RTPCR. Amplification  cycle  were as in A. (C) KU812  were 
treated with PMA (10 ng/ml), calcium ionophore  (1 #M), and the combi- 
nation for 6 h. HMC-1  cells  were  treated  similarly,  but for 3 h. Amplification 
cycles used were 32 (IL-13) and 21 (G3PDH). 
or not IL-13 was expressed in cloned mast cell  lines.  IgE-, 
PMA-, or A23187-mediated stimulation of the cloned mast 
cell line C1.MC/C57.1  resulted in high level accumulation 
of IL-13 RNA (Fig.  1 B),  whereas little or none was ob- 
served in MC/9 or PT-18 (data not shown),  two mast cell 
lines which fail  to express many of the cytokines observed 
for C1.MC/C57.1  (18) and BMMC (P. Burd,  unpublished 
observation). At 21 cycles of amplification,  a small amount 
of  IL-13-specific  product  was  detected  in  unstimulated 
C1.MC/C57.1, which increased within 15 min after antigen 
cross-linking of IgE; levels peaked by 2 h (,,o155-fold  induc- 
tion over unstimulated)  and declined thereafter.  Treatment 
with either cycloheximide or cyclosporin A (CSA) substan- 
tially interfered with RNA accumulation  at  1 h  (81%  and 
93% inhibition, respectively). IL-4 RNA induction in these 
cells displayed kinetics similar to those of IL-13, but some- 
what lesser sensitivities to the effects of cycloheximide (48% 
inhibition)  and CSA (73%  inhibition)  than  were observed 
for IL-13. RNA stability experiments indicated a half-life of 
,,o50  min  at  maximal  induction  for  IL-13  mRNA  in 
C1.MC/C57.1  (data not  shown).  Together,  these findings 
suggest  that  IL-13 expression in response to IgE-mediated 
signals  may be of short duration.  A similar pattern of short 
RNA half-life and limited period of expression has been ob- 
served for other IgE-inducible genes in mast cells, including 
TNF-o~,  IL-3,  and  IL-5  (26). 
Expression of IL-13 RNA was not unique to murine mast 
cells, as IL-13 KNA was detected in response to the combi- 
nation of PMA and calcium ionophore (but to neither agent 
alone) in the immature HMC-1. (Induction through IgE was 
not possible in this cell line, as these cells do not express FceRI 
[15].)  In the human basophilic cell line KU812 stimulated 
with PMA, IL-13 RNA was also detected, which was fur- 
ther  increased by cotreatment  with  ionophore  (Fig.  1 C). 
These  results  indicate  that  mast  cells  of both  murine  and 
human  origins are capable of expressing IL-13 RNA in re- 
sponse to IgE or pharmacologic stimulation.  Moreover, ad- 
ditional experiments examining  the signal requirements for 
IL-13 expression (data not shown) indicate that BMMC and 
C1.MC/C57.1  respond  similarly to  treatment  with  PMA, 
calcium ionophore,  and the combination,  and to the drugs 
cycloheximide and CSA. These results suggest that C1.MC/ 
C57.1 is an appropriate model for expression of this cytokine 
by mast  cells. 
Mast Cells Secrete IL-13 Proliferative  Bioactivity.  To deter- 
mine whether the IL-13 mRNA expression we detected in 
stimulated mast cells was associated with secretion of IL-13 
bioactivity, we examined the ability of mast cell-conditioned 
supernatants  to  stimulate  proliferation  of a human  IL-13- 
dependent cell line, TF- 1 (21). Direct demonstration of IL-13 
bioactivity using  antimurine  IL-13 neutralizing  antibodies 
could not be performed, as this reagent was unavailable. How- 
ever, use of a human cell line allowed us to take advantage 
of the fact that routine cytokines are generally inactive with 
human cells, but IL-13 shows full cross-species reactivity (14). 
Thus, while TF-1 responds to several other human cytokines 
1376  Mast Cell Interleukin 13 (including  GM-CSF  and IL-3), it does not respond to the 
murine homologues produced in these experiments. Prolifer- 
ation assays were performed using TF-1 cells maintained in 
rhlL-13.  After a 48-h period of IL-13 starvation, cells were 
exposed to mast cell-conditioned supernatants for 42 h and 
then  pulsed  with  [3H]thymidine  for  6  h.  Fig.  2  shows 
proliferation data obtained from the same experiments pre- 
sented in Fig. 1 and is representative of three experiments. 
IL-13 bioactivity was not observed in supernatants from un- 
stimulated cells, nor from cells exposed to IgE alone. After 
cross-linking of IgE with antigen, IL-13 bioactivity was not 
observed at 30 min, by which time preformed stores of TNF-oe 
were secreted (26, 27), but was detected by 1 h, with peak 
secretion attained by 3 h in BMMC and, later, in C1.MC/ 
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Figure 2.  Immunologically activated  mast cell supernatants  contain IL-13 
proliferative bioactivity.  Supernatants  collected from  BMMC  (A)  and 
C1.MC/C57.1  (B) stimulated wtih lgE plus antigen for the times indi- 
cated were assayed for  IL-13 proliferative activity  on TF-I cells. Data 
presented are derived from the experiment presented in Fig. I and are rep- 
resentative of three independent experiments  showing similar results. 
C57.1. Proliferation of TF-1 cells in response to rhlL-13 was 
observed at 1 ng/ml, a threefold induction over growth factor 
starved cells, and showed a dose response through 0.1 ng/ml 
under the conditions  used. We also used this assay to esti- 
mate the amount of IL-3 secreted by determining the amount 
of mast  cell supernatant  required  to cause maximal TF-1 
proliferation.  The data presented in Fig. 2 show that max- 
imal proliferation of TF-1 cells equivalent to 1 ng/ml rhlL-13 
was achieved  using 50% supernatants collected from BMMC 
at 3, 6, or 12 h, suggesting that BMMC secreted ,,o2 ng/ml. 
In separate experiments,  C1.MC/C57.1  supernatants  from 
6 or 12 h induced maximal proliferation at 5%, suggesting 
that these cells secreted as much as 20 ng/ml IL-13 bioac- 
tivity. In comparison,  BMMC secreted 0.5 ng/ml IL-4 by 
12 h, as shown by an IL-4-specific ELISA. These results dem- 
onstrate that mast cells secrete large amounts of IL-13 in re- 
sponse to stimulation through the IgE receptor and suggest 
that IL-13, like IL-4, may be a primary component of IgE- 
mediated mast cell responses. 
Mast Cell Supernatants Containing  IL-13 Bioactivity  Can Regu- 
late IgE Expression.  Using an independent bioassay to verify 
the presence of IL-13, we investigated whether murine mast 
cell supernatants were able to direct IgE production in B cells, 
a documented activity of IL-13 (7). As in the proliferation 
assay described above, human lymphocytes  were used so that 
other murine cytokines in the mast cell supernatants, partic- 
ularly IL-4, would not interfere with assessment of IL-13 
bioactivity.  The isotype switch from expression of IgM to 
IgE is preceded by a developmental stage in which the C~ 
gene is transcribed from a promoter upstream of the switch 
region of the e locus (Se), producing a "sterile" or "germ- 
line" transcript  (gCe).  This promoter is regulated by IL-4 
and may account for the role of this cytokine in switching 
to IgE expression. However, while IL-4 (or, perhaps, IL-13) 
may be necessary for this isotype switch, an additional signal 
is also required; in our experiments, this signal was supplied 
by CD40 engagement with an antibody. When switch recom- 
bination occurs joining S# to Se, the promoter of the gCe 
is deleted; at this stage, transcription  of the Ce is initiated 
by the promoter upstream of the VH region, yielding produc- 
tive e heavy chain transcripts (pCe).  Using RTPCR assays, 
we investigated the regulation ofgCe and pCe accumulation 
in B lymphocytes by mast cell supernatants.  As shown in 
Fig. 3, gCe were increased in B cells exposed to either IL-4 
or mast cell supernatant. Activation of the mast cells by IgE 
plus antigen had little effect on the ability of the superna- 
tants to induce gCe (C57 stim. vs. C57), but such activation 
significantly increased the level of pCe. IL-4 has been found 
to stimulate gCe accumulation at concentrations at least 100 
times lower than those required to induce switch recombi- 
nation (Thyphronitis,  G., F. C. Mills, and E. E. Max, un- 
published results). It is possible that IL-13 is similar in this 
respect, so that even unstimulated mast cells make enough 
IL-13 to induce gCe expression, but no switching and, there- 
fore, no pCe. It is also possible that other cytokines with 
weak cross-species reactivity might be present in these su- 
pernatants (such as TNF-o~ or TGF-~) and contribute to gCe 
1377  Burd et al. Figure  3.  Mast cell supernatants  contain  IL-13 bioactivity regulating 
IgE expression in human B lymphocytes. Human B lymphocytes purified 
from PBMC (B0) were stimulated with anti-CD40 alone, or, in addition, 
cultured  with IL-4,  supernatants  from resting  C1.MC/C57.1  (C57), or 
stimulated C1.MC/C57 (C57 stira.) and examined for expression of germ- 
line Ce, transcripts (gCe), VH5-containing CE transcripts (pCe), and S/z- 
Se DNA class switching.  RTPCR samples were normalized  for expres- 
sion of G3PDH. DNA from the lgE-secreting  cell lines 2C4 and U266 
(diluted  10 -3 with neutrophfl  DNA) was included  to demonstrate  de- 
tection  of S#-Se switch  recombination. 
transcription (28), although such effects have not been charac- 
terized. 
The idea that mast cells require activation for their super- 
natants to induce #-e switching is supported by the direct 
assay  of S#-Se junctions  by PCR  (Fig.  3,  bottom panel), 
showing that the supernatant from unstimulated mast ceils 
induced very little switch recombination, compared with the 
supernatant from mast cells stimulated by IgE plus antigen. 
Similarly, mast cell activation was required to elicit significant 
IgE secretion, in response to either C1.MC/C57.1  (Table 2) 
or BMMC (Table 3) supernatants. Treatment of B cells with 
either anti-CD40  antibody alone,  or in combination with 
supernatant from unstimulated mast cells,  did not lead to 
appreciable IgE secretion, whereas cotreatment with super- 
natants from mast cells treated with IgE plus antigen, like 
IL-4, did. (In the experiment presented in Fig. 3 and in Table 
2 as Donor 2, IL-4 induced more secretion, but less switching, 
than the supernatant from stimulated C1.MC/C57.1  cells; 
this was not observed for other donors, and similar quantita- 
tive dissociation between secretion and switching has been 
reported in a murine system [29]).  These results show that 
activated mast cells not only accumulate IL-13 mRNA, but 
also secrete a protein with two independent IL-13 bioactivi- 
ties: supporting the growth of an IL-13-dependent cell line 
and inducing IgE expression. 
Discussion 
In this report, we demonstrate that mast cells accumulate 
IL-13 mRNA and secrete significant amounts of IL-13 after 
stimulation through the IgE receptor. The induction of IL- 
13  RNA  is rapid,  beginning as early as  15 min after IgE 
receptor cross-linking,  peaking between 1 and 2 h, and falling 
substantially by 6 h.  This relatively short period of RNA 
expression is similar to that observed for IL-4 and TNF-o~ 
in mast cells, but differs from the time course of IL-13 RNA 
expression in T  cells, which persists  at high levels through 
72 h after several activation stimuli (14). However, as is seen 
in T cells, secretion of IL-13 bioactivity by mast cells closely 
parallels appearance of RNA, occurring in mast cells as early 
as I h after stimulation and reaching levels of bioactivity ap- 
proaching "~1-2 ng IL-13/106 cells. Mast cell-derived IL-13 
demonstrates several biologic activities described for T cell- 
derived IL-13:  It supports growth of the IL-13-dependent 
TF-1  cell line,  and, in B cells,  induces gCe accumulation, 
/~-e switch recombination, and IgE secretion. 
The biologic properties of IL-13 and the amounts secreted 
after stimulation suggest that mast cell-derived IL-13  may 
be a physiologically significant mediator of  mast cell responses. 
The in vitro experiments presented here indicate that sub- 
stantial levels of IL-13  are secreted by 3  h  after IgE cross- 
linking,  the same time at which in vivo studies of passive 
Table  2,  Activated  CI.MC/C57,1  Supernatants Stimulate IgE secretion 
Anti-CD40  Anti-CD40  +  IL-4  Anti-CD40  +  C57  Anti-CD40  +  Stim C57 
Donor  1  -0.47  _+  0.06  17.9  _+  3.7  1.19  +  0.76  15.1  _+  3.2* 
Donor  2  0.59  _+  1.28  20.6  _+  4.5  0.77  +  1.55  3.6  _+  1.1" 
Donor  3  0.10  +  0.02  12.6  _+  5.5  0.15  +  0.14  5.7  +  1.8" 
Purified B cells were seeded at 2  x  l0  s cells/well in microtiter plates and stimulated with anti-CD40  antibodies, rhlL-4  (10 ng/ml), or CI.MC/C57.1 
supernatants  (50%) as indicated.  Results are reported as the mean plus standard deviation of quintuplicate  determinations  and reported as nanograms 
per milliliter IgE detected  by ELISA. 
* Significantly greater than corresponding  same donor treated with anti-CD40 alone with P <0.05 by Student's  t test corrected for unequal variances. 
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Anti-CD40  Anti-CD40  +  IL-4  Anti-CD40  +  BMMC  Anti-CD40  +  Stim BMMC 
Donor 4  -0.093  +_ 0.010  1.159  _+ 0.186  -0.050  +_ 0.019  0.615  +_ 0.291" 
Donor 5  -0.086  _+ 0.004  0.466  +_ 0.256  -0.070  _+ 0.017  0.754  +_ 0.376* 
Purified B cells were treated  as in Table 2 with anti-CD40 antibodies,  rhlL-4, or BMMC supernatants  (100%)  as indicated.  Results are reported 
as the mean  plus  standard  deviation  of quintuplicate  determinations  and  are reported in nanograms  per milliliter IgE detected  by ELISA. 
* Significantly greater than corresponding  same donor treated with anti-CD40 alone with P <0.01 by Student's t test corrected for unequal variances. 
cutaneous anaphylaxis have shown inflammatory cells (mono- 
cytes, neutrophils,  and others) beginning to infiltrate sites 
of mast cell degranulation (30, 31). Like IL-4, IL-13 exhibits 
immunosuppressive effects upon monocytes, inhibiting pro- 
duction of proinflammatory cytokines, chemokines, and hema- 
topoietic growth factors, including IL-1,  IL-6, IL-8, IL-10, 
IL-12, TNF-cz, macrophage inflammatory protein-lcx, GM- 
CSF, and granulocyte-CSF (10, 11). IL-13 also decreases NO 
production and increases parasite survival in macrophages (11). 
These properties  suggest that  one function of mast cell- 
derived IL-13 may be to inhibit cytokine production by in- 
filtrating inflammatory cells recruited to sites  of mast cell 
degranulation, thereby dampening their potential for ampli- 
fication of cytokine responses at these sites. 
Although we have demonstrated that IL-13 derived from 
mast cells is able to modulate the IgE response by promoting 
class switching to IgE, the contribution of this cytokine to 
IgE responses in vivo is not dear. As murine B cells do not 
possess receptors for IL-13 (14), mast cell-derived IL-13 could 
not contribute directly to murine IgE responses.  However, 
mast cell-derived IL-13 may contribute to IgE responses in 
humans and to the development of elevated IgE levels associated 
with certain pathologic conditions, such as parasitic infec- 
tions. In this scenario, long-term or chronic antigenic stimu- 
lation of mast cells could result in amounts of IL-13 (as well 
as IL-4) suf~cient to skew the Ig response towards IgE. A 
physiologic role for IL-13 regulation of IgE is consistent with 
a reinterpretation of recent data (9) linking the IL-4 gene 
with a genetic locus regulating serum IgE levels in atopic 
humans: Since the IL-13  gene is within 30 kb of the IL-4 
gene, it is possible that the relevant allelic differences regu- 
late the function of IL-13, rather than IL-4. Other gene linkage 
studies indicate that mutations within the antigen receptor 
activation motif of the cytoplasmic tail of the high af~nity 
IgE receptor/3 subunit may also be associated with the atopic 
state (32). Such mutations might modulate cytokine produc- 
tion in response to receptor signaling, leading to increased 
or prolonged production of these IgE-inducible cytokines. 
By either mechanism, these studies suggest that mast cell 
cytokine production may be involved in either the establish- 
ment or development of allergic diseases. 
In summary, we have demonstrated that mast cells pro- 
duce significant levels of IL-13 after immunological stimula- 
tion and that mast cell-derived IL-13 is biologically active 
to direct B cell Ig class switching to lgE. The high levels 
of IL-13, relative to IL-4, secreted by mast cells, the shared 
activities of these two cytokines, and their similar biologic 
potencies (14) suggest that effects previously ascribed solely 
to IL-4 during mast cell function may be mediated, in part, 
through IL-13. 
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